Arcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.
Follow RCUS
Arcus Biosciences, Inc. (RCUS) EV/Sales
As of 16 October 2026, Arcus Biosciences, Inc. (RCUS) trades at a EV/Sales of 18.7×. Over the past ten years it has ranged from −1.9× (April 2025) to 97.4× (May 2020); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | 325.68% |
| FY2024 | 1.6× | (77.08%) |
| FY2023 | 7.0× | 38.61% |
| FY2022 | 5.0× | (20.61%) |
| FY2021 | 6.3× | (30.41%) |
| FY2020 | 9.1× | (46.40%) |
| FY2019 | 17.0× | 21.81% |
| FY2018 | 13.9× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 28.1× | 233.70% |
| Mar 2026 | 8.4× | 23.96% |
| Dec 2025 | 6.8× | 127.82% |
| Sep 2025 | 3.0× | 1,472.98% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| DNLI Denali Therapeutics Inc. compare | 8.6× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.4× |
| RCUS Arcus Biosciences, Inc. | 18.7× |
| PGEN Precigen, Inc. compare | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)